Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 25 clinical trials
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis

total immunoglobulin E (IgE) and Aspergillus-specific IgE concentrations To evaluate the effects of dupilumab on Fractional exhaled Nitric Oxide (FeNO) levels To evaluate safety and

  • 28 Oct, 2022
  • 64 locations
Efficacy of Artemisia Pollen Specific Allergen Immunotherapy

Allergic rhinitis (AR) is a noninfectious inflammatory disease of the nasal mucosa mediated by immunoglobulin E (IgE) after exposure to allergens. Artemisia annua is one of the most important

  • 04 Jun, 2022
Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis

Eosinophilic Esophagitis (EoE) is a food driven non-immunoglobulin E (IgE) mediated disease involving eosinophils and type 2 inflammation. Current therapies include diet and the off label use of

  • 07 Oct, 2022
  • 1 location
Cholinergic Urticaria - Efficacy of Dupilumab (CHED)

The purpose of this study is to assess the efficacy in reducing disease activity and safety of Dupilumab in adult patients with cholinergic urticarial (CholU) who are symptomatic despite H1-antihistamine treatment (licensed dose).

  • 29 May, 2022
  • 7 locations
Clinical Study of Allergic Rhinitis Therapy by Stem Cells

The investigators is now carrying out a clinical study of Umbilical cord Mesenchymal Stem Cells (UCMSCs) in the treatment of Allergic rhinitis (AR). UCMSCs is known to its multilineage differentiation potential, strong proliferation ability, low immunogenicity, convenient material acquisition, and fewer restrictions on ethical and moral issues. The investigators hope …

  • 07 Jul, 2022
  • 1 location
Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma. (PREDICTUMAB)

Pragmatic trial to define the magnitude and the predictive factors of the response to omalizumab and mepolizumab in adult patients with severe refractory asthma and eligible to both therapies.

  • 12 Feb, 2022
  • 1 location
Low Dose Multi-Nut Oral Immunotherapy in Pre-schoolers With a Multi-Nut Allergy

The LMNOP trial will be a 2-armed, open-label, randomised controlled trial (RCT), 2:1. Over a period of 18 months, children in the Multi-Nut Oral Immunotherapy Treatment (OIT) Group (experimental arm) will undergo low dose OIT to two nuts they are allergic to. At this time, children in the Standard Care …

  • 24 Nov, 2021
  • 1 location
Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects

This phase Ia study is meant to evaluate the tolerability, safety, pharmacokinetics, preliminary pharmacodynamics, and immunogenicity of single-dose JYB1904, an anti-immunoglobulin E (IgE

Accepts healthy volunteers
  • 04 Oct, 2022
  • 1 location
Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency

This study is trying to find out if an undetectable serum immunoglobulin E (IgE) is a biomarker, or early sign of, the development of immune deficiency.

immune globulin
Accepts healthy volunteers
serum ige
  • 24 May, 2022
  • 1 location
Immunological Response After Shrimp Oral Immunotherapy Treatment

Oral immunotherapy is effective in desensitized food allergy. Shrimp allergy is increasing in Thailand. So the purpose of our study is to determine level of specific immunoglobulin E antibodies

  • 07 Oct, 2022
  • 1 location